IVT Reaffirms FY23 Core FFO

InvenTrust has updated its 2023 guidance, as summarized in the table below. (Unaudited, dollars in thousands, except per share

InvenTrust has updated its 2023 guidance, as summarized in the table below.

(Unaudited, dollars in thousands, except per share amounts)

Current

 

Previous

Net Income per diluted share (1)

$0.06

$0.11

 

$0.23

$0.28

NAREIT FFO per diluted share (2)

$1.64

$1.69

 

$1.64

$1.69

Core FFO per diluted share

$1.59

$1.64

 

$1.59

$1.64

Same Property NOI (“SPNOI”) Growth

3.50 %

5.00%

 

3.50 %

5.00%

General and administrative

$31,250

$32,750

 

$31,250

$32,750

Interest expense, net (3)

$34,500

$35,500

 

$34,500

$35,500

Adjustments for uncollectibility (4)

50 bps

150 bps

 

50 bps

150 bps

Net investment activity (5)

~ $150,000

 

~ $150,000

Total
0
Shares
Related Posts
Read More

Hepion Pharmaceuticals Announces Restructuring Plan To Enhance Shareholder Value And Management Changes; Reducing Operating Costs By ~60% Going Forward. Hepion Will Incur A One-Time Restructuring Charge Of ~$400K–$800K That Will Be Recorded In Q4 Of 20…

Restructuring program purpose is to preserve capital and optimize clinical development programManagement plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account current market

HEPA